Europe Movers: ASM, Aston Martin, Capita, Casino Group, Glanbia, Halfords, Just Eat, Reckitt

Inga Muller
28 Feb, 2024
Frankfurt

European market indexes traded mixed and the eurozone economic sentiment indicator unexpectedly fell in February. 

ASM International declined 3.6% to €559.30 after the Dutch semiconductor equipment maker's current quarter revenue fell short of market expectations. 

Lanxess AG dropped 4.7% to €22.97 after the company said it plans to take a good impairment charge of €413 million linked to polymer additives and flavors and fragrances business units. 

Just Eat Takeaway.com dropped 5.9% to €14.17, despite the food delivery company reporting a narrower loss in the last year. 

Reckitt Benckiser plunged 10% to 5,253.0 pence after the consumer products maker reported fourth-quarter comparable sales that fell short of market expectations. 

Aston Martin Lagonda Global Holdings declined 1.9% to 173.20 pence after the luxury sports car maker delayed its plans to launch an electric car by a year. 

Vodafone Group rose 1.6% to 69.42 pence after the company said it was in advanced talks to sell its Italian arm to Swisscom for cash.

Glanbia Plc increased 2.5% to €15.79 after the dietary supplement company reported a 20% increase in full-year after-tax profit. 

Halfords dropped by 31% to 138.20 pence after the vehicle repair and maintenance company trimmed its 2024 profit outlook. 

Taylor Wimpey declined 2.4% to 136.70 pence after the UK-based housebuilder reported a decline in pre-tax profit for fiscal year 2023. 

Capita PLC increased 3.6% to 20.74 pence after the outsourcing company a European telecom service provider has enlarged its current contract. 

Casino Guichard Perrachon dropped 15% to €0.60 after the troubled retailer reported deeper losses in 2023. 

Worldline SA plunged 9.3% to €11.12 after the payment processing company reported a loss of €1.15 billion due to a goodwill impairment linked to its merchant services activities. 

Nicox SA dropped 1.1%, and the ophthalmology company appointed veteran biotech executive Gavin Spencer as the company's chief executive.